Salvage radiation plus hormone therapy with or without rezvilutamide for rising PSA
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether adding a new oral hormone blocker (rezvilutamide) to standard salvage radiation and hormone therapy can better control prostate cancer that has come back (rising PSA) after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 40 or older.
- You had surgery to remove your prostate, and the cancer was confirmed as adenocarcinoma (the most common type).
- Your PSA level dropped below 0.1 ng/mL after surgery but then rose again to over 0.2 ng/mL at least twice, with no clear signs of cancer spread on standard scans.
- You have at least one risk factor, such as a high CAPRA-S score (6 or more), a Gleason score of 8-10, PSA above 0.5, or certain advanced features in your pathology.
- You have not had hormone therapy or pelvic radiation before, and your overall health is good (ECOG 0-1, life expectancy over 10 years).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests rezvilutamide in men whose prostate-specific antigen (PSA) starts rising again after the prostate has been removed. It aims to see whether this treatment can help prevent or slow cancer spread after surgery, especially in men without signs of spread on scans.
This trial tests how well salvage radiation therapy works for prostate cancer that has come back after surgery. It looks at whether adding hormone therapy based on PSA response improves outcomes.
This trial tests the best way to treat prostate cancer that has come back after initial treatment (like surgery or radiation) and shows a few spots on a PSMA scan. It compares different salvage treatments, possibly including radiation and hormone therapy, to slow the cancer's growth.
This trial compares two schedules of hormone treatment (ADT) along with salvage radiation after prostate cancer surgery, to see which one controls cancer better over the long term. It may help people who have a rising PSA level after surgery but no spread found yet.
This trial tests giving early salvage radiotherapy (a type of radiation) to men whose PSA rises after prostate removal, but before it shows up on scans. It aims to see if starting treatment early, based on molecular markers, is more effective than waiting.
This trial uses a special scan (PSMA-PET) to find where prostate cancer has returned after surgery. Then doctors give a lower dose of radiation only to that area, which may reduce side effects. It is for men whose PSA level is rising after prostate removal.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.